Company research
PRECIGEN, INC.
CIK 1356090Updated Sep 27, 2026
SecurityPGEN · NASDAQ · equity
Name history
INTREXON CORP · through Jan 22, 2020
PGEN price & chart
Loading TradingView…
NASDAQ:PGEN on TradingView ↗In the news
Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 News provided by Precigen, Inc. Nov 06, 2025, 16:30 ET Share this article Share to X Share this article Share to X GERMANTOWN, Md. , Nov. 6, 2025 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN ), a ↗
Recent filings
4 filing
4 filing
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02
Show 5 more recent filings
144 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
4 filing
4 filing
SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding PRECIGEN, INC.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 155,505,000Source | 145,266,000Source | 151,043,000Source | 215,977,000Source |
| Property, Plant and Equipment, NetUSD | 13,758,000Source | 13,831,000Source | 7,111,000Source | 7,329,000Source |
| GoodwillUSD | 15,232,000Source | 19,139,000Source | 26,612,000Source | 36,923,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 3,182,000Source | 4,455,000Source | 40,701,000Source | 44,455,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 30,234,000Source | 29,517,000Source | 7,578,000Source | 4,858,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,916,000Source | 926,000Source | 902,000Source | 959,000Source |
| Assets, CurrentUSD | 115,235,000Source | 102,414,000Source | 68,755,000Source | 118,159,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,434,000Source | 3,341,000Source | 4,325,000Source | 4,779,000Source |
| Operating Lease, Right-of-Use AssetUSD | 4,679,000Source | 5,056,000Source | 7,097,000Source | 8,086,000Source |
| Other Assets, NoncurrentUSD | 908,000Source | 371,000Source | 767,000Source | 1,025,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 134,594,000Source | 78,535,000Source | 32,545,000Source | 89,718,000Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 2,362,252,000Source | 2,129,207,000Source | 2,084,916,000Source | 1,998,314,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,341,348,000Source | -2,090,706,000Source | -1,964,471,000Source | -1,868,567,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 7,000Source | 12,000Source | -1,947,000Source | -3,488,000Source |
| Stockholders' Equity Attributable to ParentUSD | 20,911,000Source | 38,513,000Source | 118,498,000Source | 126,259,000Source |
| Liabilities and EquityUSD | 155,505,000Source | 145,266,000Source | 151,043,000Source | 215,977,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 37,306,000Source | 21,518,000Source | 22,985,000Source | 78,645,000Source |
| Operating Lease, Liability, CurrentUSD | 1,136,000Source | 956,000Source | 1,202,000Source | 1,209,000Source |
| Accounts Payable, CurrentUSD | 11,985,000Source | 3,531,000Source | 1,726,000Source | 4,068,000Source |
| Operating Lease, Liability, NoncurrentUSD | 3,980,000Source | 4,546,000Source | 5,895,000Source | 6,992,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | 0Source | 1,847,000Source | 2,263,000Source |
| Other Liabilities, NoncurrentUSD | 134,000Source | — | — | — |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 100,369,000Source | 97,910,000Source | 62,900,000Source | — |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 1,847,000Source | 2,263,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 93,174,000Source | — | — | 0Source |
| Long-term Debt, Current MaturitiesUSD | — | — | — | 43,219,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 93,174,000Source | — | — | 0Source |
| Short-term InvestmentsUSD | 67,624,000Source | 68,393,000Source | 55,277,000Source | 51,092,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | 28,317,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,199,000Source | 4,526,000Source | 6,668,000Source | 10,765,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,866,000Source | 9,471,000Source | 9,888,000Source | 10,206,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 2,990,000Source | 24,000Source | -76,000Source | 2,229,000Source |
| Increase (Decrease) in InventoriesUSD | 9,209,000Source | — | — | -2,341,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | -1,795,000Source | -479,000Source | -150,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -87,831,000Source | -68,173,000Source | -66,930,000Source | -65,045,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -1,535,000Source | -20,714,000Source | -3,087,000Source | 226,417,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 1,995,000Source | 8,584,000Source | 1,536,000Source | 4,924,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,776,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 90,048,000Source | 110,583,000Source | 29,589,000Source | -155,292,000Source |
| Repayments of Long-term DebtUSD | 0Source | 0Source | 43,219,000Source | 154,705,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 717,000Source | 21,669,000Source | -40,748,000Source | 5,253,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 30,234,000Source | 29,517,000Source | 7,848,000Source | 48,596,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 3,510,000Source | 7,000Source | 1,171,000Source | 8,535,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 35,000Source | -27,000Source | -320,000Source | -827,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,866,000Source | 9,471,000Source | 9,888,000Source | 10,206,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 356,000Source | 0Source | 60,000Source | 1,042,000Source |
| Amortization of Intangible AssetsUSD | 1,273,000Source | 3,059,000Source | 4,848,000Source | 4,798,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 100,369,000Source | 97,910,000Source | 62,900,000Source | — |
| Deconsolidation, Gain (Loss), AmountUSD | — | -2,915,000Source | — | — |
| DepreciationUSD | 1,926,000Source | 1,467,000Source | 1,820,000Source | 2,393,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | -139,523,000Source | — | — | — |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | -139,523,000Source | — | — | — |
| Gain (Loss) on Disposition of AssetsUSD | -14,000Source | 2,000Source | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | 72,000Source | -421,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | 0Source | 60,000Source | 961,000Source |
| GoodwillUSD | 15,232,000Source | 19,139,000Source | 26,612,000Source | 36,923,000Source |
| Goodwill, Impairment LossUSD | 3,907,000Source | 7,409,000Source | 10,390,000Source | 482,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -79,777,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 0Source | 0Source | 108,094,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | 0Source | 0Source | 862,000Source |
| Income Tax Expense (Benefit)USD | 3,000Source | -1,793,000Source | -458,000Source | -189,000Source |
| InterestExpenseNonoperatingUSD | 3,867,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -250,642,000Source | -126,235,000Source | -95,904,000Source | 28,317,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -429,642,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -140,132,000Source | — | — | — |
| Operating ExpensesUSD | 120,191,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 43,000Source | 8,500,000Source | — | — |
| Payments to Acquire InvestmentsUSD | 208,006,000Source | 187,206,000Source | 185,026,000Source | 0Source |
| Proceeds from Issuance of Common StockUSD | -355,000Source | 31,237,000Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | 92,818,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 1,202,000Source | 346,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 9,684,000Source | — | — | 26,909,000Source |
| Selling, General and Administrative ExpenseUSD | 70,128,000Source | — | — | — |
| Operating Income (Loss)USD | -110,507,000Source | — | — | — |
| Other Nonoperating Income (Expense)USD | 43,000Source | 8,500,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -250,639,000Source | -128,028,000Source | -96,362,000Source | -79,966,000Source |
| Income Tax Expense (Benefit)USD | 3,000Source | -1,793,000Source | -458,000Source | -189,000Source |
| Net Income (Loss) Attributable to ParentUSD | -250,642,000Source | -126,235,000Source | -95,904,000Source | 28,317,000Source |
| Earnings Per Share, BasicUSD per share | -1.37Source | -0.47Source | -0.39Source | 0.14Source |
| Earnings Per Share, DilutedUSD per share | -1.37Source | -0.47Source | -0.39Source | 0.14Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 312,980,562Source | 267,727,426Source | 244,536,221Source | 200,360,821Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 312,980,562Source | 267,727,426Source | 244,536,221Source | 200,360,821Source |
| Interest Expense (non-operating)USD | 3,867,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,273,000Source | 3,059,000Source | 4,848,000Source | 4,798,000Source |
| Current Income Tax Expense (Benefit)USD | 3,000Source | — | — | — |
| Goodwill, Impairment LossUSD | 3,907,000Source | 7,409,000Source | 10,390,000Source | 482,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -79,777,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -250,719,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -0.47Source | -0.39Source | -0.4Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -0.47Source | -0.39Source | -0.4Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | 0Source | 0Source | 108,094,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | 0Source | 0Source | 862,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -429,642,000Source | — | — | — |
| Nonoperating Income (Expense)USD | -140,132,000Source | — | — | — |
| Operating ExpensesUSD | 120,191,000Source | — | — | — |
| Research and Development ExpenseUSD | 41,333,000Source | — | — | — |
Filing attachments
tm2524946d1_ex99-1.htm · 8-K · 2025-09-03
EX-99.1 3 tm2524946d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Announces Up to $125 Million Non-Dilutive Financing $100 million funded at close fortifies balance sheet and supports robust US commercialization of PAPZIMEOS, as well as potential expansion into international markets and the pursuit of pediatric and other HPV-related indications GERMANTOWN, MD, September 3, 2025 -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative pr…
Read attachment ↗tm2523710d1_ex99-1.htm · 8-K · 2025-08-18
EX-99.1 2 tm2523710d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 US FDA Approval of PAPZIMEOS August 18, 2025 ────────────────────── 2 Forward-looking Statement This presentation contains “forward-looking” statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “s…
Read attachment ↗